about
A neurotoxic glycerophosphocholine impacts PtdIns-4, 5-bisphosphate and TORC2 signaling by altering ceramide biosynthesis in yeastUsing neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer's Disease.Molecular nutrition research: the modern way of performing nutritional scienceMetabolic profiles of biological aging in American Indians: the Strong Heart Family StudyBiofluid lipidome: a source for potential diagnostic biomarkers.The future of blood-based biomarkers for Alzheimer's disease.Emerging biomarkers in cognition.Metabolite profiling in posttraumatic stress disorder.ESI-MS/MS and MALDI-IMS Localization Reveal Alterations in Phosphatidic Acid, Diacylglycerol, and DHA in Glioma Stem Cell XenograftsAltered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease.Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD).Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study.Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disordersMass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology.High resolution mass spectrometry based techniques at the crossroads of metabolic pathways.Recent advances in lipidomics for disease research.Biomarkers in Sporadic and Familial Alzheimer's Disease.Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease.Analytical approaches for lipidomics and its potential applications in neuropsychiatric disorders.Metabolomic-guided discovery of Alzheimer's disease biomarkers from body fluid.Dietary DHA supplementation causes selective changes in phospholipids from different brain regions in both wild type mice and the Tg2576 mouse model of Alzheimer's disease.Interplay of Energetics and ER Stress Exacerbates Alzheimer's Amyloid-β (Aβ) Toxicity in Yeast.Lipidomics of human umbilical cord serum: identification of unique sterol sulfatesTargeted Lipidomics of Fontal Cortex and Plasma Diacylglycerols (DAG) in Mild Cognitive Impairment and Alzheimer's Disease: Validation of DAG Accumulation Early in the Pathophysiology of Alzheimer's Disease.Plasma lipidomics of tuberculosis patients: altered phosphatidylcholine remodeling.Lysophospholipid-Related Diseases and PPARγ Signaling Pathway.Is Lipidomic the Answer to the Search of a Biomarker for Organ Preservation Protocol in Head and Neck Squamous Cell Carcinoma?Improvement of spatial learning and memory, cortical gyrification patterns and brain oxidative stress markers in diabetic rats treated with Ficus deltoidea leaf extract and vitexin.Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer's disease subjects.Imaging mass spectrometry of frontal white matter lipid changes in human alcoholics.Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease.Lipidomic analysis of immune activation in equine leptospirosis and Leptospira-vaccinated horses.Plasma metabolomic biomarkers accurately classify acute mild traumatic brain injury from controls.Serum lipidomics of bovine paratuberculosis: Disruption of choline-containing glycerophospholipids and sphingolipids.
P2860
Q28539054-F2149113-2891-44E1-8749-0E1852950F62Q30451918-25D108C0-B885-419F-98DC-3C2F574A1A76Q30458970-50321FA6-A9C8-4C07-9999-68EA6C59B390Q33577707-A63F03A4-349D-40A7-9B8A-BCC60DB13B32Q33822645-ABBF7D7B-2804-4B0E-86A3-597538810CACQ34026317-5DD6B294-B668-4D46-A199-52E2A744391DQ35008258-935835A0-5D26-4A06-8FE6-B0300FB2AD7DQ35200833-2109052D-784D-4328-A316-C4635494F80EQ35603809-C9846C88-6B10-4E21-9053-928E0C1B24C2Q36355644-A4476DE0-4038-45DF-B94F-6C8CB66771DCQ36713818-A524E31D-ACB1-4F37-8093-0C651AFCC6F9Q37091714-6A9FA89C-E8A6-4A00-9533-989DF9569F08Q37199221-F2BECA67-8955-4EFA-A285-1F16BE51F24EQ38120648-A4957EB0-B9C5-4FD5-A9A6-02AA46134AFBQ38167286-C955F890-6E55-4317-A17C-8645A31BCEDDQ38591116-47B3EAFE-7717-46C4-BBDF-0210599F245FQ38592041-1EDD5354-810C-47BC-827C-431BEC418B60Q38619618-62796E6E-FB03-45F5-BFC5-1803E0126A36Q38629703-668FA322-22BD-4F19-8EEF-4A2DF0A9311CQ39181900-58EDC18D-EA9A-40EC-B8CC-82E7E648671CQ39928314-4E762CE2-1095-4ECC-9931-BE990103855CQ41140219-2266311C-E45C-4AE6-84F8-13FA67C90B56Q41609264-9DFE41FE-5B8B-4471-8D19-3912EC963049Q41934251-D14CAE5A-D0BD-4408-ADCD-4721EA40FD5BQ47132185-4078A254-C88C-4571-8101-5BC46432FCD4Q47191829-EB669CD4-5F01-4FEC-8F4B-EE682D07D522Q47610361-B51B2BF3-B2E5-4FB8-81E5-F5780F62EA03Q47722159-6B004100-4D9E-4BFE-BA53-88EEDF671E2DQ48237879-DFAE20DA-C273-47E7-BD0C-16184458B386Q50050920-14C52FD4-8E54-43B8-BAAC-FB35B1FBFC26Q51761574-7E89D048-B382-457F-B369-81E6277AF192Q52688310-D8D5E76C-2979-4D65-B3F2-9FFA35E8AA07Q53405822-ECB5115F-2A64-491D-A0E8-82E2EF74ACD8Q53821082-0F88679C-D89B-412D-AB75-5700F66FA566
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Lipidomics of Alzheimer's disease: current status.
@en
Lipidomics of Alzheimer's disease: current status.
@nl
type
label
Lipidomics of Alzheimer's disease: current status.
@en
Lipidomics of Alzheimer's disease: current status.
@nl
prefLabel
Lipidomics of Alzheimer's disease: current status.
@en
Lipidomics of Alzheimer's disease: current status.
@nl
P2860
P356
P1476
Lipidomics of Alzheimer's disease: current status.
@en
P2093
Paul L Wood
P2860
P2888
P356
10.1186/ALZRT103
P407
P577
2012-02-01T00:00:00Z
P5875
P6179
1009603503